Medical Journals

5'-amp-activated Protein Kinase Activation Prevents Postischemic Leukocyte-endothelial Cell Adhesive Interactions.

Authors:
  • Gaskin F Spencer
  • Kamada Kazuhiro
  • Yusof Mozow
  • Korthuis Ronald J

From: Dept. of Medical Pharmacology and Physiology, Univ. of Missouri-Columbia, 1 Hospital Dr., Columbia, MO 65212, USA. korthuisr@health.missouri.edu

American journal of physiology. Heart and circulatory physiology

  • Publish Date: Jan 2007
  • ISSN: 0363-6135
  • Volume: 292
  • Issue: 1
  • Pages: H326-32
  • Medium: Print
  • Language: English
  • Citation (JAMA): Gaskin F Spencer, Kamada Kazuhiro, Yusof Mozow, et al. 5'-amp-activated Protein Kinase Activation Prevents Postischemic Leukocyte-endothelial Cell Adhesive Interactions.. Am. J. Physiol. Heart Circ. Physiol. Jan 2007;292:H326-32

Abstract

Preconditioning (PC) with nitric oxide (NO) donors or agents that increase endothelial NO synthase (eNOS) activity 24 h before ischemia-reperfusion (I/R) prevents postischemic leukocyte rolling (LR) and stationary leukocyte adhesion (LA). Since 5’-AMP-activated protein kinase (AMPK) phosphorylates eNOS at Ser1177, resulting in activation, we postulated that AMPK activation may trigger the development of a preconditioned anti-inflammatory phenotype similar to that induced by NO donors. Wild-type (WT) C57BL/6J and eNOS(-/-) mice were treated with the AMPK agonist 5-aminoimidazole-4-carboxamide 1-beta-d-furanoside (AICAR) 30 min (early AICAR PC) or 24 h (late AICAR PC) before I/R; LR and LA were quantified in single postcapillary venules in the jejunum using intravital microscopy. I/R induced comparable marked increases in LR and LA in WT and eNOS(-/-) mice relative to sham-operated (no ischemia) animals. Late AICAR PC prevented postischemic LR and LA, whereas early AICAR PC prevented LA in WT mice. Late AICAR PC was ineffective in preventing I/R-induced LR but not LA in the eNOS(-/-) mice, and the same pattern was seen in WT animals treated with the NOS inhibitor N(omega)-nitro-l-arginine. Early AICAR PC remained effective in preventing LA in eNOS(-/-) mice. Our results indicate that both early and late PC with an AMPK agonist produces an anti-inflammatory phenotype in postcapillary venules. Since the protection afforded by late AICAR PC on postischemic LR was prevented by NOS inhibition in WT mice and absent in eNOS-deficient mice, it appears that eNOS triggers this protective effect. In stark contrast, antecedent AMPK activation prevented I/R-induced LA by an eNOS-independent mechanism.

Mesh Headings (Keywords): Aminoimidazole Carboxamide, Animals, Cell Adhesion, Endothelial Cells, Enzyme Activation, Ischemic Preconditioning, Myocardial, Leukocytes, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Multienzyme Complexes, Myocardial Reperfusion Injury, Protein-Serine-Threonine Kinases, Ribonucleotides, Treatment Outcome


Check for Full Text / PubMed Unique Identifier (PMID): 16935999


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.